UY29127A1 - Nuevos derivados de pirimidina y su uso - Google Patents

Nuevos derivados de pirimidina y su uso

Info

Publication number
UY29127A1
UY29127A1 UY29127A UY29127A UY29127A1 UY 29127 A1 UY29127 A1 UY 29127A1 UY 29127 A UY29127 A UY 29127A UY 29127 A UY29127 A UY 29127A UY 29127 A1 UY29127 A1 UY 29127A1
Authority
UY
Uruguay
Prior art keywords
pyrimidine
treatment
new derivatives
diseases
prophylaxis
Prior art date
Application number
UY29127A
Other languages
English (en)
Inventor
Dr Hilmar Bischoff
Dr Axel Kretschmer
Dr Klemens Lustig
Dr Elke Dittrich-Wengenroth
Dieter Lang
Dr Marcus Bauser
Lars Barfacker
Dr Ulrich Rosentreter
Dr Peter Ellinghaus
Claudia Hirt-Dietrich
Martin Raabe
Christian Pilger
Stephan Bartel
Armin Kern
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY29127A1 publication Critical patent/UY29127A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a nuevos derivados de pirimidina, a procedimientos para su preparación, a su uso para el tratamiento y/o la profilaxis de enfermedades, así como a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, preferentemente para el tratamiento y/o la prevención de enfermedades cardiovasculares, en particular, dislipidemias, arteriosclerosis, insuficiencia cardíaca, trombosis y síndrome metabólico.
UY29127A 2004-09-25 2005-09-23 Nuevos derivados de pirimidina y su uso UY29127A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004046623A DE102004046623A1 (de) 2004-09-25 2004-09-25 Neue Pyrimidin-Derivate und ihre Verwendung

Publications (1)

Publication Number Publication Date
UY29127A1 true UY29127A1 (es) 2006-04-28

Family

ID=35063041

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29127A UY29127A1 (es) 2004-09-25 2005-09-23 Nuevos derivados de pirimidina y su uso

Country Status (22)

Country Link
US (1) US20080261990A1 (es)
EP (1) EP1797045A1 (es)
JP (1) JP2008514559A (es)
KR (1) KR20070055621A (es)
CN (1) CN101065364A (es)
AR (1) AR051295A1 (es)
AU (1) AU2005287589A1 (es)
BR (1) BRPI0517327A (es)
CA (1) CA2582492A1 (es)
DE (1) DE102004046623A1 (es)
EC (1) ECSP077340A (es)
GT (1) GT200500266A (es)
IL (1) IL182136A0 (es)
MA (1) MA28882B1 (es)
MX (1) MX2007003428A (es)
NO (1) NO20072051L (es)
PE (1) PE20060657A1 (es)
RU (1) RU2007115215A (es)
SV (1) SV2007002235A (es)
TW (1) TW200628451A (es)
UY (1) UY29127A1 (es)
WO (1) WO2006032384A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254036A1 (en) 2007-04-13 2008-10-16 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
KR100813387B1 (ko) * 2007-06-26 2008-03-12 신명곤 부형제 첨가없이 인삼농축액으로 유동성 및 저장성이우수한 인삼농축액환 제조 방법
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション PPARδアゴニストの胎児再プログラミング用途
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN103130732A (zh) * 2011-11-22 2013-06-05 上海博康精细化工有限公司 3,5-二甲基-4-氯甲基异噁唑的制备方法
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
WO2020167958A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Methods for treating cholestasis
CN115598267B (zh) * 2022-12-13 2023-05-09 山东省食品药品检验研究院 一种格列齐特中潜在遗传毒性杂质的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035682T2 (de) * 1999-04-28 2008-04-30 Sanofi-Aventis Deutschland Gmbh Di-aryl-säurederivate als ppar rezeptor liganden
GB0214254D0 (en) * 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CN101065364A (zh) 2007-10-31
CA2582492A1 (en) 2006-03-30
ECSP077340A (es) 2007-04-26
SV2007002235A (es) 2007-03-20
PE20060657A1 (es) 2006-08-12
JP2008514559A (ja) 2008-05-08
EP1797045A1 (de) 2007-06-20
BRPI0517327A (pt) 2008-10-07
US20080261990A1 (en) 2008-10-23
MX2007003428A (es) 2008-03-13
WO2006032384A1 (de) 2006-03-30
DE102004046623A1 (de) 2006-03-30
AR051295A1 (es) 2007-01-03
RU2007115215A (ru) 2008-11-10
IL182136A0 (en) 2007-07-24
MA28882B1 (fr) 2007-09-03
GT200500266A (es) 2006-05-11
AU2005287589A1 (en) 2006-03-30
KR20070055621A (ko) 2007-05-30
NO20072051L (no) 2007-06-07
TW200628451A (en) 2006-08-16

Similar Documents

Publication Publication Date Title
UY29127A1 (es) Nuevos derivados de pirimidina y su uso
ECSP077357A (es) Procedimiento para la preparación de 4-{4-[cloro-3-(trifluorometil) fenil] amino}carbonil)amino]fenoxi}n-metilpiridina-2-carboxamida
DOP2006000062A (es) Derivados de acido pirimidincarboxilico y su uso
UY29099A1 (es) Fenilaminotiazoles sustituidos y su uso
AR058098A1 (es) Derivados de acidos dicarboxilicos y su uso
CR20110485A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
ECSP055524A (es) Derivados de indolin-fenilsufonamida
UY31228A1 (es) Ariloxazoles sustituidos y su uso
UY31484A1 (es) Piperidinas heteroaril-sustituidas
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
ECSP11011483A (es) Piperidinas sustituidas
ECSP088569A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
UY30582A1 (es) Derivados de acido 2-fenoxinicotinico y su uso
CR20110627A (es) Piperidinas sustituidas
UY28115A1 (es) Derivados del acido isoftalico
WO2011141113A3 (de) Kombination aus vitamin k und nikotinamid
DOP2005000177A (es) Nuevos derivados de pirimidina y su uso
EA200970293A1 (ru) Новые производные 5-тиоксилопиранозы
EA200970292A1 (ru) Производные 5-тиоксилопиранозы и их применение в терапии
DOP2005000174A (es) Fenilaminotiazoles sustituidos y su uso
DOP2003000663A (es) Derivados de indolinfenilsulfonamida
HN2008000946A (es) Nuevos derivados de furopirimidina aciclicos sustituidos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160530